Morepen Laboratories Limited
NSE: MOREPENLAB · Healthcare · Pharmaceuticals · Market cap ₹5,403 Cr
₹98.60+4.25 (+4.50%)
· Prev close ₹94.35 · Volume 4.52 L · 52W ₹33–151
NSE: MOREPENLAB · Healthcare · Pharmaceuticals · Market cap ₹5,403 Cr
· Prev close ₹94.35 · Volume 4.52 L · 52W ₹33–151
If profit compounds at 10.0% (CAGR) and the stock ends at 25×, buying at ₹99 returns about 8.5% CAGR over 10 years.
| Growth assumption | Profit growth (CAGR) | Return, 10Y CAGR |
|---|---|---|
| Yours | 10.0% | 8.5% |
| Delivered FY22–26 | — | — |
| Net profit, last 4 quarters vs the 4 before | — | — |
| Half the delivered pace | — | — |
This is an exit-multiple calculation, not a discounted cash flow. Inputs: EPS for the 4 quarters Dec 2025 to Sep 2026 ₹3.43, price ₹98.60 (9 Nov 2026, 10:54 am IST price). Formula: return = (EPS × exit P/E ÷ price)^(1/10) × (1 + growth) − 1. Net profit growth is applied to EPS, so the share count is held constant. A profit fall of 100% or more has no rate and is left blank. Dividends ignored. Arithmetic, not a forecast.